Pérez-Rodríguez Almudena, García-Rivero Aranzazu, Lourés Esther, López-Fernández Maria Fernanda, Rodríguez-Trillo Angela, Batlle Javier
Servicio de Hematología y Hemoterapia, Complexo Hospitalario, Universitario Juan Canalejo (Edificio Hospital Materno Infantil), Carretera del Pasaje s/n, La Coruña, Spain.
Haematologica. 2009 May;94(5):679-86. doi: 10.3324/haematol.2008.003301. Epub 2009 Mar 13.
Mutation C1149R in the von Willebrand factor (VWF) gene has been thought to cause autosomal dominant severe type 1 von Willebrand disease (VWD).
Eight patients from three unrelated families with this mutation were included in the present study who had distinct VWF abnormalities, not described in earlier studies.
The patients showed notably low levels of VWF antigen (VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo), VWF collagen binding (VWF:CB), and a reduced ristocetin-induced platelet aggregation (RIPA). VWF:RCo/VWF:Ag and VWF:CB/VWF:Ag ratios were lower than 0.7. At basal conditions, all the VWF multimers were decreased in plasma, with a clearly lower relative proportion of the high molecular weight VWF multimers (HMWM). In high-resolution agarose gels, a large decrease in the relative proportions of the satellite bands was seen. The patients had a brief good response to desmopressin (DDAVP) administration, but the released VWF half-life was shorter than normal, indicating an accelerated clearance of their VWF. Platelet VWF was abnormal.
We conclude from the results obtained in these patients for plasma phenotypic data that this mutation should be classified as a VWD type 2A (IIE). DDAVP therapy may be somewhat helpful for this mutation, at least for mild to moderate bleeding. These data provide evidence that for VWD classification factors other than basal VWF, such as DDAVP response and platelet VWF, should be considered.
血管性血友病因子(VWF)基因中的C1149R突变被认为会导致常染色体显性遗传的严重1型血管性血友病(VWD)。
本研究纳入了来自三个无亲缘关系家庭的八名携带此突变的患者,他们具有先前研究中未描述的独特VWF异常情况。
患者的VWF抗原(VWF:Ag)、VWF瑞斯托霉素辅因子活性(VWF:RCo)、VWF胶原结合能力(VWF:CB)水平显著降低,瑞斯托霉素诱导的血小板聚集(RIPA)减少。VWF:RCo/VWF:Ag和VWF:CB/VWF:Ag比值低于0.7。在基础状态下,血浆中所有VWF多聚体均减少,高分子量VWF多聚体(HMWM)的相对比例明显更低。在高分辨率琼脂糖凝胶中,可见卫星带的相对比例大幅下降。患者对去氨加压素(DDAVP)给药有短暂的良好反应,但释放的VWF半衰期短于正常水平,表明其VWF清除加速。血小板VWF异常。
根据这些患者血浆表型数据的结果,我们得出结论,该突变应归类为2A型(IIE型)VWD。DDAVP治疗可能对该突变有一定帮助,至少对轻度至中度出血有效。这些数据证明,对于VWD分类,除了基础VWF外,还应考虑其他因素,如DDAVP反应和血小板VWF。